Search Results

CHOLESTEROL: Reagent kit intended for the quantitative determination of Cholesterol in human serum. Cholesterol measurements are used in the diagnosis and treatment of disorders involving excess cholesterol in the blood, of lipid and lipoprotein metabolism disorders.

HDL-Cholesterol: Reagent kit intended for the quantitative determination of high-density lipoprotein in human serum. Measurements are used in the diagnosis and treatment of lipid disorders mellitus), atherosclerosis, and various liver and renal diseases.

LDL-Cholesterol: Reagent kit intended for the quantitative determination of low-density lipoprotein in human serum. Lipoprotein measurements are used in the diagnosis and treatment of lipid disorders (such as diabetes mellitus), atherosclerosis, and various liver and renal diseases.

TRIGLYCERIDES: Reagent kit intended for the quantitative determination of triglycerides (neutral fat) in human serum. Measurements are used in the diagnosis and treatment of patients with diabetes mellitus, nephrosis, liver obstruction, other diseases involving lipid metabolism, or various endocrine disorders.

CHOLESTEROL: The Cholesterol Oxidase peroxidase (CHOD-PAP) enzymatic method is used. The cholesterol esterase enzyme catalyzes the hydrolysis of cholesterol and free fatty and free fatty acids. Free cholesterol, including that originally present in the sample, is then oxidized by the enzyme cholesterol oxidase (CHOD) to cholest-4-en-3-one, by using molecular oxygen as the electron acceptor and concurrently producing hydrogen peroxide (H2O2). The H2O2 produced is then used in a subsequent chromogenic oxidative coupling reaction, catalyzed by the enzyme peroxidase, in the presence of a redox indicator system, which leads to the formation of a colored compound, absorbing light at 550 nm. The increase in absorbance is directly proportional to the cholesterol concentration in the sample.

HDL-Cholesterol: The Accelerator Selective Detergent method is applied. The determination of HDL-Cholesterol is based on the following reactions: LDL, VLDL, and chylomicrons are neutralized by the combined action of the enzymes Cholesterol Oxidase, Peroxidase, accelerators and N,N-bis-(4-sulfobutyl)-m-toluidine-disodium (DSBmT). HDL remaining in the sample is disrupted by the action of a selective detergent and cholesterol is converted to △4 Cholestenone by the enzymatic action of Cholesterol Esterase and Cholesterol Oxidase, with the subsequent production of H2O2, which reacts with DSBmT and 4-aminoantipyrine in the presence of Peroxidase to a colored complex that absorbs light at 590 nm. The absorbance measured is proportional to the concentration of HDL-Cholesterol in the sample.

LDL-Cholesterol: The Selective Detergent method is applied. The method is in a two-reagent format and depends on the properties of a unique detergent. The first detergent solubilizes only the non-LDL lipoprotein particles. The cholesterol released is consumed by cholesterol esterase and cholesterol oxidase in a non-color forming reaction. The second detergent solubilizes the remaining LDL particles, and a chromogenic coupler allows for color formation. The enzyme reaction with LDL-Cholesterol in the presence of the coupler at 590 nm produces color that is proportional to the amount of LDL cholesterol present in the sample.

TRIGLYCERIDES: The enzymatic glycerol-3-phosphate-peroxidase (GPO-POD) method is used. The method enzymatically hydrolyzes by lipase to free fatty acids and glycerol is phosphorylated by adenosine triphosphate (ATP) with glycerokinase (GK) to produce glycerol-3-phosphate and adenosine diphosphate (ADP). Glycerol-3-phosphate-oxidase oxidizes glycerol-3-phosphate to dihydroxyacetone phosphate and H2O2. The catalytic action of peroxidase (POD) forms quinoneimine from H202, aminoantipyrine, and Dihydrate (N-Ethyl-N-(2hydroxy-3-sulfopropyl)-m-toluidine (TOOS). The absorption change at 550 nm is proportional to the triglycerides concentration in the sample.

Here's a breakdown of the acceptance criteria and the study information for the Medicon Hellas Cholesterol, HDL-Cholesterol, LDL-Cholesterol, and Triglycerides test systems, based on the provided document:

1. Table of Acceptance Criteria and Reported Device Performance

The acceptance criteria are generally established by comparison to legally marketed predicate devices and alignment with clinical laboratory guidelines (CLSI). The document presents a clear comparison in the "Device Comparison Table" sections. For this summary, I'll focus on the key performance indicators for each analyte.

CHOLESTEROL

HDL-Cholesterol

LDL-Cholesterol

TRIGLYCERIDES

2. Sample size used for the test set and the data provenance

• Accuracy (Method Comparisons):

  • A minimum of 75 leftover specimens.
  • For the specific analytes:
    • CHOLESTEROL: 93 human serum samples
    • HDL-Cholesterol: 141 human serum samples
    • LDL-Cholesterol: 107 human serum samples
    • TRIGLYCERIDES: 163 human serum samples
  • Data Provenance: The document states "left-over specimens," implying retrospective use of clinical samples. The country of origin is not explicitly stated, but the company is Medicon Hellas, S.A. based in Greece, and testing was performed at the company premises.

• Precision/Reproducibility:

  • Three human serum pools for Cholesterol and Triglycerides.
  • Two pools for HDL-Cholesterol.
  • Four pools for LDL-Cholesterol.
  • Each sample was tested for 20 testing days, two different runs, and two replicate measurements per run (morning and afternoon run), for a total of 80 results per level concentration (e.g., for Cholesterol, 3 pools * 80 results/pool = 240 results).
  • Data Provenance: Human serum pools, likely prepared in-house or acquired for the study.

• Linearity:

  • 11 to 13 levels per analyte, prepared by dilution of a human serum pool.
  • Each level was tested in 4 replicates.
  • Data Provenance: Human serum pool.

• Analytical Specificity / Interference:

  • Serum pools at low and high levels of each analyte.
  • Each measurement of the blank and the sample containing the interferent was repeated at least 5 times.
  • Data Provenance: Serum pools.

• Detection Limit:

  • LoB: 5 blank serum samples measured in 4 replicates for 3 days (total of 60 measurements).
  • LoD: 5 low-level samples measured in 4 replicates for 3 days (total of 60 measurements).
  • LoQ: 10 samples that span the low end of linearity, measured 5 times each day for 3 days (total of 150 measurements).
  • Data Provenance: Serum samples.

• Stability and Calibration Frequency:

  • Two fresh serum pools and two serum-based commercial controls.
  • Measurements were repeated in triplicate at regular time points.
  • Data Provenance: Serum pools and commercial controls.

3. Number of experts used to establish the ground truth for the test set and the qualifications of those experts

This information is not provided in the document. The ground truth for performance studies like those described (method comparison, precision, linearity, interference, detection limits) for in vitro diagnostic (IVD) devices like these typically involves established reference methods or highly accurate comparative analyzers, rather than expert human interpretation of results. The document states that the performance of the Medicon Hellas reagents was compared with "comparator methods" (Beckman Coulter reagents on AU400, Abbott Diagnostics reagents on Architect c8000), which serve as the reference for ground truth in these types of analytical performance studies. The qualifications of the operators performing these studies are not specified.

4. Adjudication method for the test set

This information is not applicable and therefore not provided. Adjudication methods (e.g., 2+1, 3+1) are typically used in studies where human interpretation of complex data (like medical images) is involved and a consensus is needed to establish ground truth. For quantitative chemical assays, the ground truth is established by the highly precise and accurate measurement of reference methods or predicate devices.

5. If a multi-reader multi-case (MRMC) comparative effectiveness study was done, If so, what was the effect size of how much human readers improve with AI vs without AI assistance

This information is not applicable and therefore not provided. MRMC studies are specific to evaluating diagnostic devices where human readers interpret medical cases, often with and without AI assistance (e.g., radiology AI). The Medicon Hellas devices are in vitro diagnostic reagents for quantitative chemical measurements in serum, not image-based diagnostic tools that require human "readers" in the context of an MRMC study.

6. If a standalone (i.e. algorithm only without human-in-the-loop performance) was done

This concept is not applicable in the traditional sense for these in vitro diagnostic reagents. These devices are chemical assays that produce a quantitative numerical output (e.g., cholesterol level in mg/dL). There isn't an "algorithm" making a diagnostic interpretation independently in the way AI software would. The device is the standalone measurement system. Its performance is evaluated independently through analytical studies (precision, linearity, accuracy against reference methods, etc.). The results are then read and interpreted by a human clinician.

7. The type of ground truth used

The ground truth for the analytical performance studies (precision, linearity, interference, detection limits, and method comparison) was established against:

• Reference Methods/Predicate Devices: For method comparison, the device's performance was compared against established comparator methods (Beckman Coulter reagents on AU400 and Abbott Diagnostics reagents on ABBOTT Architect c8000). The document explicitly states these as the comparators.
• A Priori Values/Established Standards: For linearity, precision, and detection limits, the ground truth is based on the known concentrations of prepared samples (e.g., serially diluted pools, spiked samples, blank serum) and statistical analysis according to CLSI guidelines.
• Traceability to Reference Methods/Materials: For Cholesterol and Triglycerides, traceability is to Gas-chromatography-isotope dilution mass spectrometry (GC-IDMS). For HDL-Cholesterol and LDL-Cholesterol, traceability is to the Abell-Kendall (AK) reference method.

8. The sample size for the training set

This information is not applicable and therefore not provided. These are chemical reagent kits, not machine learning (AI/ML) models that require a "training set" in the computational sense. The development of such reagents involves chemical and enzymatic research and optimization, often tested with various batches and concentrations of samples during R&D. The studies described in this document are for validation and verification of the final device, not for "training" an algorithm.

9. How the ground truth for the training set was established

As noted above, the concept of a "training set" with ground truth established in the AI/ML sense is not applicable to these chemical reagent devices. The "ground truth" for evaluating the analytical performance of the developed reagent kits is established through the reference methods and standardized protocols described in section 7.

Ask a specific question about this device

The Cholesterol2 assay is used for the quantitation of cholesterol in human serum or plasma on the ARCHITECT c System. The Cholesterol2 assay is to be used as an aid in the diagnosis and treatment of disorders involving excess cholesterol in the blood and lipid and lipoprotein metabolism disorders.

The Cholesterol2 assay is an automated clinical chemistry assay for the quantitation of cholesterol in human serum or plasma on the ARCHITECT c System. Cholesterol esters are enzymatically hydrolyzed by cholesterol esterase to cholesterol and free fatty acids. Free cholesterol, including that originally present, is then oxidized by cholesterol oxidase to cholest-4-ene-3-one and hydrogen peroxide. The hydrogen peroxide oxidatively couples with N,N-Bis(4-sulfobutyl)-3-methylaniline (TODB) and 4-aminoantipyrine to form a chromophore (quinoneimine dye) which is quantitated at 604 nm.

The provided text describes the Abbott Cholesterol2 assay, an in vitro diagnostic device for quantifying cholesterol in human serum or plasma.

Here's an analysis of the acceptance criteria and study data:

1. Table of Acceptance Criteria and Reported Device Performance

The document does not explicitly state pre-defined acceptance criteria for each performance characteristic. Instead, it presents the results of various studies as proof of device performance. The table below summarizes the reported performance, which implicitly serves as the "met" criteria.

2. Sample size used for the test set and the data provenance (e.g. country of origin of the data, retrospective or prospective)

• Precision Study: 2 controls and 3 human serum panels were tested. Each sample was tested in duplicate, twice per day for 20 days. This means 80 measurements per sample (2 duplicates x 2 times/day x 20 days).
• Lower Limits of Measurement Study: n ≥ 60 replicates for LoB, LoD, and LoQ determinations. They used low-analyte level samples and zero-analyte samples.
• Linearity Study: The number of samples for the linearity study is not explicitly stated, but it covered the range of 5 to 748 mg/dL.
• Interference Studies: Each endogenous substance was tested at 2 analyte levels (approximately 150 mg/dL and 220 mg/dL). Exogenous substances were tested at various specified interferent levels. The number of samples for each interferent is not provided.
• Method Comparison Study: 138 serum samples were used.
• Tube Type Study: Samples were collected from a minimum of 40 donors.
• Dilution Verification: 8 human serum samples.

Data Provenance: The document does not specify the country of origin of the data or whether the studies were retrospective or prospective. Given the context of medical device regulatory submission, these are typically prospective studies conducted in a controlled laboratory environment. The "human serum panels" and "human serum samples" imply human-derived biological samples.

3. Number of experts used to establish the ground truth for the test set and the qualifications of those experts (e.g. radiologist with 10 years of experience)

This device is an in vitro diagnostic (IVD) chemistry assay. The concept of "experts establishing ground truth" as it applies to image interpretation or clinical diagnosis by medical professionals (like radiologists) does not directly apply here in the same way.

For IVDs like this, the "ground truth" or reference values are established through:

• Reference methods: The Cholesterol2 reagent is certified to be traceable to the National Reference System for cholesterol, against the Abell-Kendall reference method in a CDC-Certified Cholesterol Reference Method Laboratory Network (CRMLN). The Abell-Kendall method is considered the gold standard for cholesterol measurement.
• Analytically Validated Methods: For values outside the AMI but within the EMI, samples were "value assigned using the analytically validated method."
• Known concentrations: For studies like linearity, spiked samples with known concentrations are used.

Therefore, the "experts" are the methodologists and laboratory professionals overseeing and validating the reference methods and the analytical validation processes. No specific number or qualification of clinical experts (e.g., radiologists) is relevant for establishing the ground truth for a quantitative chemistry assay.

This is a standalone performance evaluation of the assay itself, demonstrating its analytical accuracy, precision, and robustness.

4. Adjudication method (e.g. 2+1, 3+1, none) for the test set

The concept of "adjudication" (e.g., 2+1, 3+1 where multiple human readers agree or have a tie-breaker by an expert) is not applicable to this type of quantitative diagnostic assay. The results are numerical values generated by the automated instrument and reagents. Deviations or discrepancies would be resolved through re-testing, quality control, or investigation into instrument or reagent issues, rather than human expert adjudication of a "diagnosis."

5. If a multi-reader multi-case (MRMC) comparative effectiveness study was done, If so, what was the effect size of how much human readers improve with AI vs without AI assistance

No, an MRMC comparative effectiveness study was not done. This is an in vitro diagnostic assay, not an AI-powered diagnostic imaging device or an AI assistant for human readers. Its output is a quantitative measurement of cholesterol, not an interpretation that requires human "reading" or decision support.

6. If a standalone (i.e. algorithm only without human-in-the loop performance) was done

Yes, a standalone performance evaluation of the device (Cholesterol2 assay on the ARCHITECT c8000 System) was done. The studies described (reportable interval, precision, lower limits of measurement, linearity, interference, method comparison, tube type, dilution verification) all evaluate the analytical performance of the assay and instrument directly, without human interpretation as part of the primary outcome measure. The output is a numerical concentration of cholesterol.

7. The type of ground truth used (expert consensus, pathology, outcomes data, etc)

The ground truth used for this quantitative assay primarily relies on:

• Reference Methods: Specifically, the Abell-Kendall reference method, which is considered the gold standard for cholesterol measurement and is used in CDC-Certified Cholesterol Reference Method Laboratory Networks (CRMLN). The device's traceability to this method is explicitly stated.
• Analytically Validated Methods: For verifying values in the extended measuring interval.
• Known Spiked Concentrations: For studies such as linearity and dilution verification, where samples are prepared with precisely known concentrations.

This is an analytical ground truth, not a clinical ground truth derived from pathology or patient outcomes.

8. The sample size for the training set

This document does not describe a typical "training set" in the context of machine learning or AI. This is a chemistry assay that uses reagents and enzymatic reactions, not an algorithm that is "trained" on data. Therefore, the concept of a training set as used in AI development is not applicable here. The assay's analytical characteristics are determined through standard laboratory validation studies.

9. How the ground truth for the training set was established

As explained above, there is no "training set" in the AI sense for this device. The analytical accuracy and reliability are established through comparisons to certified reference methods and known standard concentrations, as described in point 7.

Ask a specific question about this device

For the quantitative in vitro determination of Cholesterol in serum and plasma. Cholesterol measurements are used in the diagnosis and treatments of disorders involving excess cholesterol in the blood and lipoprotein metabolism disorders.

The Cholesterol kit assay consists of ready to use reagent solutions.

CATALOGUE NUMBER: CH8310

R1. Reagent 4 x 20 ml

REAGENT COMPOSITION

Contents: R1. Reagent 4-Aminoantipyrine, Phenol, Peroxidase (E.C.1.11.1.7, Horse Radish, +25°C), Cholesterol esterase (E.C.3.1.1.13. Pseudomonas, +37°C), Cholesterol oxidase (E.C.1.1.3.6. Nocardia, +37°C), Sodium Azide

Concentrations in the Test: 0.25 mmol/l, 6.00 mmol/l, >=0.50 U/ml, >= 0.20 U/ml, >=0.10 U/ml, 0.09%

MATERIALS REQUIRED BUT NOT PROVIDED: Randox Assayed Multisera Level 2 (Cat. No. HN 1530) and Level 3 (Cat. No. HE 1532); 510(k) # K942458, Randox Calibration Serum Level 3 (Cat. No. CAL 2351); 510(k) # K053153, RX series Saline (Cat. No. SA 8396)

Here's a breakdown of the acceptance criteria and study information for the Randox Laboratories Ltd. Cholesterol device, based on the provided FDA 510(k) summary:

1. Table of Acceptance Criteria and Reported Device Performance

The document doesn't explicitly state "acceptance criteria" for all tests in a single table, but rather presents the performance results of various analytical studies that demonstrate the device's capability. I've compiled the relevant performance data from the document into a table, noting the implicit acceptance measures (e.g., meeting CLSI guidelines, certain correlation coefficients, or imprecision percentages).

2. Sample Sizes and Data Provenance for the Test Set

• Precision/Reproducibility:
  • Controls: Not explicitly stated as "sample size" but data is reported for commercial control materials (717UE, 724UE, 952UN).
  • Patient Samples: 4 concentrations of unaltered human serum samples (3 diluted, 1 spiked for Linearity Pool, 1 Sensitivity Pool). Each sample run in 2 replicates per run, twice per day for 20 non-consecutive days, using 2 reagent lots on 2 RX Daytona plus systems.
  • Data Provenance: "unaltered human serum samples" implies human origin, likely retrospective for spiking/dilution. No country of origin is specified.
• Linearity/Assay Reportable Range:
  • Sample Size: 11 levels of samples covering the measuring range. Each level run in 5 replicates.
  • Data Provenance: "linearity samples" were prepared. Implies in-vitro prepared samples to cover the range, likely based on human serum/plasma.
• Detection Limit (LoD), Limit of Blank (LoB), Limit of Quantitation (LoQ):
  • Sample Size: LoD was based on 240 determinations with 4 low-level samples.
  • Data Provenance: Not specified, but generally prepared samples for low-level determination.
• Analytical Specificity (Interference):
  • Sample Size: Not explicitly stated for the number of interferent samples, but tested at Cholesterol concentrations of 150 mg/dl and 250 mg/dl for each interferent.
  • Data Provenance: Prepared samples spiked with interferents.
• Method Comparison with Predicate Device:
  • Sample Size: 107 serum patient samples.
  • Data Provenance: "serum patient samples" spanning 25 to 599 mg/dl. Retrospective. No country of origin specified.
• Matrix Comparison:
  • Sample Size (Lithium Heparin): Minimum of 54 matched patient sample pairs (serum vs. lithium heparin plasma).
  • Sample Size (Potassium 2 EDTA): Minimum of 50 matched patient sample pairs (serum vs. potassium 2 EDTA plasma).
  • Data Provenance: "Patient samples were drawn in matched pairs". Retrospective from human subjects. No country of origin specified.

3. Number of Experts and Qualifications for Ground Truth for the Test Set

This device is an in vitro diagnostic (IVD) for quantitative measurement of cholesterol. The "ground truth" for such devices is established by precise laboratory reference methods or established commercially available controls and calibrators with known values.

• No "experts" in the sense of radiologists or pathologists establishing ground truth as would be the case for imaging devices.
• Ground truth is established by:
  • Reference materials (e.g., NIST 1952a for the calibrators, mentioned under traceability).
  • Established analytical methods used by the predicate device and in clinical laboratories.
  • CLSI guidelines for experimental design and data analysis.

4. Adjudication Method for the Test Set

Not applicable for this type of quantitative IVD device. Adjudication methods (like 2+1, 3+1) are typically used for qualitative or semi-quantitative assessments, especially in imaging or pathology, where human expert discrepancy resolution is needed. For quantitative chemical measurements, the ground truth is often numerical and objectively determined.

5. Multi-Reader Multi-Case (MRMC) Comparative Effectiveness Study

No. This is an in vitro diagnostic device for chemical analysis of cholesterol, not an imaging or qualitative assessment device involving human readers. Therefore, an MRMC study is not relevant.

6. Standalone (i.e., algorithm only without human-in-the-loop performance) Study

Yes, the entire performance evaluation presented is a standalone study of the device (Cholesterol assay on the RX Daytona plus system). The device performs the analytical measurement autonomously once the sample is loaded. The studies demonstrate the analytical performance of the device itself.

7. Type of Ground Truth Used

The ground truth for the performance studies is multi-faceted:

• Reference Materials: Randox Calibration Serum Level 3 is traceable to Cholesterol reference material NIST 1952a. This is a primary ground truth for calibration and accuracy.
• Predicate Device: For method comparison studies, the predicate device (Randox Cholesterol reagent, K923504) serves as a comparative ground truth, aiming to demonstrate substantial equivalence rather than absolute biological truth.
• CLSI Guidelines: The studies adhere to CLSI (Clinical and Laboratory Standards Institute) guidelines (EP5-A2 for precision, EP6-A for linearity, EP17-A2 for detection limits, EP9-A2 for method comparison), which represent an industry-accepted "ground truth" for how these analytical performance characteristics should be determined and evaluated.
• Prepared Samples: For linearity, sensitivity, detection limits, and interference, samples were prepared to known concentrations or spiked with known substances to create specific "ground truth" scenarios.

8. Sample Size for the Training Set

There is no mention of a "training set" in the context of machine learning or AI, as this device is a traditional in vitro diagnostic reagent system, not an AI/ML-based device.

9. How the Ground Truth for the Training Set Was Established

Not applicable, as there is no training set for an AI/ML algorithm in this context.

Ask a specific question about this device

For the quantitative measurement of triglycerides in serum. Triglycerides measurements are used in the diagnosis and treatment of patients with diabetes mellitus. nephrosis, liver obstruction and other diseases involving lipid metabolism or various endocrine disorders. For in-vitro use only.

For the quantitative measurement of Total cholesterol in serum. Cholesterol measurements are used in the diagnosis and treatment of disorders involving excess cholesterol in the blood and lipoprotein metabolism disorders. For in-vitro use only.

Not Found

This document is a 510(k) premarket notification acceptance letter from the FDA for medical devices: "Cholesterol Oxidase JAS" and "Glycerol Kinase Triglycerides." This type of document does not contain the detailed study information, acceptance criteria, or performance data typically found in a clinical study report or a summary of safety and effectiveness (SSE). The 510(k) essentially states that the FDA has reviewed the submission and found the device substantially equivalent to a legally marketed predicate device, allowing it to be marketed.

Therefore, I cannot extract the requested information from the provided text because it is not present in this regulatory acceptance letter. This document is not a study report.

Ask a specific question about this device

Cholesterol 1,2,3TM is an in vitro diagnostic test for the quantification of skin cholesterol. Cholesterol 1,2,3TM uses a detector reagent that reacts with skin cholesterol in proportion to the amount of cholesterol on the surface of the epidermis. An indicator reagent (horseradish peroxidase substrate) is added and color allowed to develop. Color intensity is proportional to the amount of bound skin cholesterol in the palmar surface of the skin. The color intensity (hue) can be measured objectively by use of a handheld reflectance spectrophotometer.

Skin cholesterol as measured by Cholesterol 1,2,3TM can be used as part of risk assessment for coronary heart disease in persons with a history of myocardial infarction and/or in persons suspected of having significant multi-vessel coronary artery disease (>50% stenosis in >1 vessel as diagnosed by coronary angiography) where further diagnostic evaluation is being considered. Test results, when considered in conjunction with clinical evaluation, blood cholesterol tests and other risk factors identified for coronary artery disease, will aid the physician in focusing diagnostic and patient management options.

The Cholesterol 1,2,3TM spectrophotometer in conjunction with the Cholesterol 1,2,3™ reagents are intended for use in the quantitative determination of cholesterol in the epidermal layer of the skin.

Here's a breakdown of the acceptance criteria and the study details for the Cholesterol 1,2,3™ device, based on the provided text:

Acceptance Criteria and Device Performance

The provided document does not explicitly state specific, quantifiable acceptance criteria (e.g., "sensitivity must be >X%", "accuracy must be >Y%"). Instead, it presents performance data in relation to the intended use. The closest indicators of "acceptance" are the statistical significance of skin cholesterol's contribution to risk and the ROC AUC for predicting multi-vessel CAD.

However, based on the Summary of Performance Data and the FDA's final decision, the implicit acceptance criteria appear to be centered around the device's ability to demonstrate:

1. Correlation with Multi-Vessel Coronary Artery Disease (CAD): Show that increasing skin cholesterol levels correlate with an increased risk of significant multi-vessel CAD, especially in certain HDL ranges.
2. Correlation with Prior Myocardial Infarction (MI): Show that increasing skin cholesterol levels correlate with an increased probability of prior MI, especially in certain HDL ranges.
3. Lack of ability to rule out CAD: Acknowledge that the test cannot be used to rule out coronary artery disease.
4. No correlation with HDL: Demonstrate that skin cholesterol measurements are independent of HDL levels.
5. Precision/Reproducibility: Demonstrate reliable and consistent measurements.
6. Safety and Effectiveness: Satisfy the FDA that the device is substantially equivalent to predicate devices for its specified indications for use, with appropriate limitations.

Here's a table summarizing the reported device performance against these implicit criteria:

Study Information

2. Sample Size Used for the Test Set and Data Provenance:

• Sample Size: 750 individuals (649 patients scheduled for coronary angiography and 101 age and gender-matched controls).
• Data Provenance: The patients were "mostly Caucasian." The document does not specify the country of origin but implies a single study cohort. The study appears to be retrospective in nature, as it uses existing angiography data and history of MI to correlate with skin cholesterol measurements.

3. Number of Experts Used to Establish the Ground Truth for the Test Set and Qualifications of Those Experts:

• Ground Truth for CAD: "significant multi-vessel coronary artery disease (>50% stenosis in >1 vessel as diagnosed by coronary angiography)." The document does not specify the number or qualifications of experts (e.g., cardiologists, interventional radiologists) who performed or interpreted the coronary angiographies.
• Ground Truth for MI: "history of myocardial infarction (MI)." The source and qualification of those who established the history of MI are not specified.

4. Adjudication Method for the Test Set:

• The document does not specify an adjudication method for the coronary angiography results or the history of MI. It simply states that disease was "diagnosed by coronary angiography" or "history of MI."

5. If a Multi-Reader Multi-Case (MRMC) Comparative Effectiveness Study was done:

• No. This study is a standalone performance study of the device itself, correlating its measurements with clinical outcomes (CAD, MI). It does not involve human readers interpreting device outputs in a comparative effectiveness setting (AI vs. without AI assistance).

6. If a Standalone (i.e., algorithm only without human-in-the-loop performance) was done:

• Yes. The study presents the performance of the Cholesterol 1,2,3™ device (spectrophotometer and reagents) in directly quantifying skin cholesterol and then correlating these quantitative measurements with clinical outcomes. There is no mention of a human-in-the-loop process for interpreting the "hue angle" measurement; it's a direct output of the device.

7. The Type of Ground Truth Used:

• Clinical Outcomes/Pathology (Angiography):
  • Coronary Artery Disease: Significant multi-vessel coronary artery disease (>50% stenosis in >1 vessel as diagnosed by coronary angiography). Angiography is considered a clinical gold standard for assessing coronary stenosis.
  • Myocardial Infarction: History of prior myocardial infarction. This is typically established through patient records, clinical diagnosis, and potentially previous diagnostic tests.
• Expert Consensus: Implied for the diagnosis from angiography/MI records, though not explicitly stated as an "expert consensus process" for this study.

8. The Sample Size for the Training Set:

• The document does not explicitly describe a separate training set for the device's development or the analysis presented. The 750 individuals appear to be the cohort used for the performance evaluation study. For the precision analysis, smaller groups (e.g., 20 candidates for within-day/day-to-day, 10 candidates for batch-to-batch) were used to validate the device's measurement consistency.

9. How the Ground Truth for the Training Set was Established:

• As no separate training set is detailed, information on how its ground truth was established is not provided. The ground truth for the evaluation was established as described in point 7.

Ask a specific question about this device

This reagent is intended for the rapid quantitative in-vitro measurement of total serum or plasma cholesterol concentration, utilizing manual or automated analyzers. The determination of serum plasma is one of the important tools in the diagnosis and classification of lipemia. Other conditions, such as hepatic and thyroid diseases, influence cholesterol levels.

Cholestero! Rapid |Liquid Reagent

This document is a 510(k) clearance letter from the FDA for a medical device called "RAICHEM Cholesterol Rapid Liquid Reagent." It does not contain information about the acceptance criteria or a study proving the device meets those criteria in the format requested.

The letter primarily:

• Confirms that the device is substantially equivalent to legally marketed predicate devices.
• States that the device can be marketed subject to general controls of the Federal Food, Drug, and Cosmetic Act.
• Provides information about applicable regulations and contact details for further inquiries.

The "Indications for Use" section (page 2 of the document) describes what the reagent is intended for: "rapid quantitative in-vitro measurement of total serum or plasma cholesterol concentration, utilizing manual or automated analyzers." It also mentions that cholesterol determination is important for diagnosing and classifying lipemia and that other conditions influence cholesterol levels.

However, the document does not include any of the following requested information:

1. A table of acceptance criteria and reported device performance.
2. Sample size used for the test set or data provenance.
3. Number of experts used to establish ground truth or their qualifications.
4. Adjudication method for the test set.
5. Information on a multi-reader multi-case (MRMC) comparative effectiveness study or effect size.
6. Information on a standalone algorithm performance study.
7. The type of ground truth used.
8. Sample size for the training set.
9. How the ground truth for the training set was established.

Therefore,Based on the provided text, I cannot provide the requested information regarding the acceptance criteria and the study proving the device meets them. The document is an FDA 510(k) clearance letter and details the regulatory approval but does not include the specifics of performance studies or acceptance criteria.

Ask a specific question about this device

Cholesterol measurements are used in the diagnosis and treatment of disorders involving excess cholesterol in the blood and lipid and lipoprotein metabolism disorders.

CHOLESTEROL REAGENT

The provided text is a 510(k) clearance letter from the FDA for a device named "CHOLESTEROL REAGENT." This document is a regulatory approval and does not contain any information regarding acceptance criteria or a study proving the device meets acceptance criteria.

The letter states that the device is "substantially equivalent" to predicate devices, which means it has been compared to a device already legally marketed. However, it does not describe the specific performance characteristics, clinical study design, or results that would be expected in a document outlining acceptance criteria and a study to meet them.

Therefore, I cannot provide the requested information based on the input text.

Ask a specific question about this device

Ask a specific question about this device